Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIS-001 ER in healthy volunteers
NCT03156439Phase 1Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- May 2017
- Primary completion
- Sep 2017
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Huperzine A in complex partial epilepsy, sponsored by Supernus Pharmaceuticals, Inc. Primary endpoints: Maximum serum concentration at 16 Weeks, Area under the curve at 16 Weeks and 4 more. Started May 2017; status: completed.
02
Drugs
Huperzine A
03
Conditions
complex partial epilepsy
Beyond the preview
Go deeper on NCT03156439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03156439.